Leveraging actionable genomic testing to ensure patients receive the proper targeted therapies quickly is crucial to improving clinical outcomes in cancer care. The ability of laboratories, hospitals, and healthcare systems to provide accurate, efficient, and cost-effective Next Generation Sequencing (NGS) technologies and diagnostic testing at the local level with rapid turnaround time, offers the promise to transform the future state of cancer care worldwide.
Pillar Biosciences is committed to measurably reducing diagnostic costs, decreasing time to treatment initiation, improving efficiencies for pathologists, and enabling better Decision Medicine™ by equipping treating physicians with the diagnostic tools and critical information needed to select the best treatment.
Randy Pritchard is the Chief Executive Officer of Pillar Biosciences. He has more than 24 years of experience with expertise in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.
Helen Fernandes, Ph.D., is the Assistant Director and Co-Director of Genomic Oncology in the Personalized Genomic Medicine Laboratory of the Columbia University Department of Pathology and Cell Biology. She is also a professor at the Columbia University Irving Medical Center (CUMC). She has previously held teaching positions at Rutgers University and Weill Cornell Medicine, and is an active member of the Association for Molecular Pathology (AMP) and American Association for Clinical Chemistry (AACC).
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.